SCHEMBL1067151

SCHEMBL1067151

CCn1c(=O)n(CCCCc2nc(-c3ccccn3)no2)c(=O)c2[nH]c(Cl)nc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 2/20 0.45
ADORA2B P29275 15/20 0.44
ADORA1 P30542 10/20 0.43
ADORA2A P29274 6/20 0.43
ADORA3 P0DMS8 5/20 0.43
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
SIRT1 Q96EB6 1/20 0.42
SIRT3 Q9NTG7 1/20 0.42
SIRT5 Q9NXA8 1/20 0.42
KDM4E B2RXH2 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
HPGD P15428 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 1/20 0.40
THPO P40225 1/20 0.40
PMP22 Q01453 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL837624 0.95 ADORA2B (0.49) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL836978 0.95 ADORA2B (0.46) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL1070506 0.91 NPC1 (0.46) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL837093 0.91 ADORA2B (0.43) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL836881 0.91 ADORA2B (0.46) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL1066470 0.91 ADORA2B (0.43) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL3115399 0.91 NPC1 (0.51) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL3114981 0.91 NPC1 (0.53) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL835236 0.90 ADORA2B (0.41) NPC1SMN1; SMN2RAB9AADORA2BADORA1
SCHEMBL3114133 0.90 NPC1 (0.43) NPC1SMN1; SMN2RAB9AADORA2BADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2272848-B1 Xanthine derivatives as selective HM74A agonists GLAXOSMITHKLINE LLC (US) 2012-12-26 EP disclosed
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GLAXOSMITHKLINE LLC 2011-10-20 US disclosed
EP-2272848-A1 Xanthine derivatives as selective HM74A agonists Glaxosmithkline LLC (US) 2011-01-12 EP disclosed
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS SMITHKLINE BEECHAM CORPORATION 2010-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257205-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS GPR84, GPR88, XDH NPC1 1312/4885SMN1; SMN2 782/4885RAB9A 1905/4885
US-20100179128-A1 XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS XDH, GPR84, GPR88 NPC1 919/4885SMN1; SMN2 761/4885RAB9A 1728/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.